Glucotrack (GCTK) Liabilities and Shareholders Equity (2010 - 2025)

Glucotrack has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $7.8 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 32.13% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.9 million (up 279.54% YoY) and the FY2025 annual result came in at $7.8 million, up 32.13% from the prior year.
• Liabilities and Shareholders Equity eased to $7.8 million in Q4 2025, from $8.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $10.2 million in Q2 2025 and troughed at $608000.0 in Q2 2024.
• A 5-year average of $5.8 million and a median of $6.1 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 93.23% — and 2025, when it surged 1579.28%.
• Tracing GCTK's Liabilities and Shareholders Equity over 5 years: stood at $6.3 million in 2021, then slumped by 61.09% to $2.4 million in 2022, then surged by 101.19% to $4.9 million in 2023, then increased by 20.94% to $5.9 million in 2024, then soared by 32.13% to $7.8 million in 2025.
• Business Quant data shows GCTK's Liabilities and Shareholders Equity at $7.8 million in Q4 2025, $8.3 million in Q3 2025, and $10.2 million in Q2 2025.